Neuromuscular Regenerative Rehabilitation Research

$1,250
12%
Raised toward our $10,000 Goal
1 Donors
21
days left
Project ends on February 14, at 11:55 PM EST
Project Owners

Neuromuscular Regenerative Rehabilitation Research

Neuromuscular Regenerative Rehabilitation Research Group

The Neuromuscular Regenerative Rehabilitation Research Group (NR3G) was started by Dr. Joseph A. Roche in 2016 to develop regenerative and rehabilitative interventions to regrow muscle that has been lost due to trauma (blast injuries), genetic muscle disease (e.g. muscular dystrophies), and aging (sarcopenia). NR3G has received research funding from the National Institutes of Health and the Alliance for Regenerative Rehabilitation Research (AR3T, an NIH-supported research alliance). NR3G is currently comprised of the Principal Investigator (PI) Dr. Roche, 12 doctor of physical therapy students, 2 bachelor of science Students, and 1 high school student.

The group has developed novel regenerative and rehabilitative techniques to regrow muscle from donor muscle cells in mouse models. Our work is likely to translate into therapies for people who have lost muscle mass and the ability to move functionally due to trauma (blast injuries), genetic muscle disease (e.g. muscular dystrophies), and aging (sarcopenia), as there are currently no therapies to reverse these processes. 

The group has made significant progress by developing therapies that have shown promise in preclinical studies.

Show support for this research group and help them continue their significant progress by donating today. 

 

More about the research

Our data provide unequivocal evidence that our novel regenerative-rehabilitation methods can promote unprecedented levels of donor-derived muscle regeneration. We are confident that stake-holders and philanthropists who have an interest in therapies for muscle regeneration will support our work. We specifically predict that, donors who might have contributed to large foundations such as the Muscular Dystrophy Association (MDA), might be inclined to contribute to our research due to the immediate translational impact and neglible administrative costs.